Rivipansel

Rivipansel (GMI-1070) is a potent E-selectin antagonist. Rivipansel prevents interaction between leukocytes and vascular endothelium. Rivipansel has the potential for the research of sickle cell vaso-occlusive crisis[1][2].

Product Specifications

CAS Number

[927881-99-0]

Product Name Alternative

GMI-1070

UNSPSC

12352005

Target

E-Selectin

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/rivipansel.html

Solubility

10 mM in DMSO

Smiles

O=C([C@H]1C[C@H]([C@@H]([C@H](C1)NC(C2=CC(NC(N2)=O)=O)=O)O[C@H]3[C@H]([C@@H]([C@@H]([C@@H](O3)C)O)O)O)O[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O[C@H](C(O)=O)CC5CCCCC5)OC(C6=CC=CC=C6)=O)NCCNC(COCCOCC(NC7=CC(S(=O)(O)=O)=CC8=C7C(S(=O)(O)=O)=CC(S(=O)(O)=O)=C8)=O)=O

Molecular Formula

C58H74N6O31S3

Molecular Weight

1447.42

References & Citations

[1]Dampier CD, et al. A Randomized Clinical Trial of the Efficacy and Safety of Rivipansel for Sickle Cell Vaso-occlusive Crisis (VOC) . Blood. 2022 Aug 18:blood.2022015797. |[2]Carlton D.DampierMD, et al. Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis. Blood, 2020, 136 (1) :18-19.